Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125859331 | 12585933 | 1 | I | 20160627 | 20160628 | 20160725 | 20160725 | PER | US-ASTRAZENECA-2016SE71359 | ASTRAZENECA | 65.55 | YR | M | Y | 81.60000 | KG | 20160725 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125859331 | 12585933 | 1 | PS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG 1 PUFF TWICE A DAY | 21929 | ||||||||||
| 125859331 | 12585933 | 2 | SS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG 2 PUFF TWICE A DAY | 21929 | ||||||||||
| 125859331 | 12585933 | 3 | SS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG 1 PUFF TWICE A DAY | 21929 | ||||||||||
| 125859331 | 12585933 | 4 | SS | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | Oral | 0 | 25 | MG | MODIFIED-RELEASE TABLET | QD | |||||||
| 125859331 | 12585933 | 5 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 125859331 | 12585933 | 6 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 125859331 | 12585933 | 7 | C | ZETIA | EZETIMIBE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 125859331 | 12585933 | 8 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD | ||||||||
| 125859331 | 12585933 | 9 | C | FLOMAX | TAMSULOSIN HYDROCHLORIDE | 1 | Oral | 0 | .4 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125859331 | 12585933 | 1 | Chronic obstructive pulmonary disease |
| 125859331 | 12585933 | 2 | Chronic obstructive pulmonary disease |
| 125859331 | 12585933 | 3 | Chronic obstructive pulmonary disease |
| 125859331 | 12585933 | 4 | Coronary artery disease |
| 125859331 | 12585933 | 5 | Coronary artery disease |
| 125859331 | 12585933 | 6 | Blood cholesterol abnormal |
| 125859331 | 12585933 | 7 | Blood cholesterol abnormal |
| 125859331 | 12585933 | 8 | Coronary artery disease |
| 125859331 | 12585933 | 9 | Benign prostatic hyperplasia |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125859331 | 12585933 | Heart rate increased | |
| 125859331 | 12585933 | Hypertension | |
| 125859331 | 12585933 | Intentional product misuse | |
| 125859331 | 12585933 | Off label use | |
| 125859331 | 12585933 | Rash |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125859331 | 12585933 | 1 | 20160615 | 0 |